Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick G Morris

Showing results (11-20 of 99) with videos related to

Pageof 10
Sort By:
Anti-Cancer Drugs|December 10, 2019
Induction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma: triplet or doublet chemotherapy?Maeve A Hennessy, Patrick G Morris
Clinical Advances in Hematology & Oncology : H&O|April 16, 2009
Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancerPatrick G Morris, Monica N Fornier
Expert Review of Anticancer Therapy|September 19, 2009
Personalizing therapy for metastatic breast cancerPatrick G Morris, Clifford A Hudis
Expert Review of Anticancer Therapy|May 13, 2014
The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiformeRichard M Bambury, Patrick G Morris
International Journal of Women'S Health|January 23, 2015
Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacyMark K Doherty, Patrick G Morris
Journal of Mammary Gland Biology and Neoplasia|September 27, 2012
Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancerElizabeth Comen, Patrick G Morris, Larry Norton
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 24, 2009
Cytotoxic chemotherapy for pregnancy-associated breast cancer: single institution case seriesPatrick G Morris, Fionnuala King, M John Kennedy
Expert Opinion on Biological Therapy|November 30, 2017
Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancerJack Patrick Gleeson, Niamh M Keegan, Patrick G Morris
Expert Opinion on Pharmacotherapy|April 9, 2009
Therapeutic options for metastatic breast cancerPatrick G Morris, Heather L McArthur, Clifford A Hudis
Breast Cancer (Dove Medical Press)|March 4, 2021
Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based ReviewAnna S Linehan, Orla M Fitzpatrick, Patrick G Morris
Pageof 10

Showing results (11-20 of 99) with videos related to

Sort By:
Pageof 10
Anti-Cancer Drugs|December 10, 2019
Induction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma: triplet or doublet chemotherapy?Maeve A Hennessy, Patrick G Morris
Clinical Advances in Hematology & Oncology : H&O|April 16, 2009
Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancerPatrick G Morris, Monica N Fornier
Expert Review of Anticancer Therapy|September 19, 2009
Personalizing therapy for metastatic breast cancerPatrick G Morris, Clifford A Hudis
Expert Review of Anticancer Therapy|May 13, 2014
The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiformeRichard M Bambury, Patrick G Morris
International Journal of Women'S Health|January 23, 2015
Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacyMark K Doherty, Patrick G Morris
Journal of Mammary Gland Biology and Neoplasia|September 27, 2012
Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancerElizabeth Comen, Patrick G Morris, Larry Norton
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 24, 2009
Cytotoxic chemotherapy for pregnancy-associated breast cancer: single institution case seriesPatrick G Morris, Fionnuala King, M John Kennedy
Expert Opinion on Biological Therapy|November 30, 2017
Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancerJack Patrick Gleeson, Niamh M Keegan, Patrick G Morris
Expert Opinion on Pharmacotherapy|April 9, 2009
Therapeutic options for metastatic breast cancerPatrick G Morris, Heather L McArthur, Clifford A Hudis
Breast Cancer (Dove Medical Press)|March 4, 2021
Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based ReviewAnna S Linehan, Orla M Fitzpatrick, Patrick G Morris
Pageof 10